ChemicalBook > CAS DataBase List > AR-A014418

AR-A014418

CAS No.487021-52-3
Chemical Name:AR-A014418
CBNumber:CB9497883
Molecular Formula:C12H12N4O4S
Formula Weight:308.31
MOL File:487021-52-3.mol

AR-A014418 Property

Melting point 208-210?C (dec.)
Density 1.464±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMSO: ≥20mg/mL, clear, light yellow
form Yellow solid
pka 5.80±0.70(Predicted)
color off-white to tan
Sensitive Light Sensitive
Stability Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.
FDA UNII 87KSH90Q6D
UNSPSC Code 12352200
NACRES NA.77

Safety

Hazard Codes :Xn
Risk Statements :22-37/38-41
Safety Statements :26-36/39
WGK Germany :3

NFPA 704:

	0
3		0

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal wordDanger
Hazard statements H302-H315-H318-H335
Precautionary statements P261-P280-P305+P351+P338-P280a-P304+P340-P405-P501a

AR-A014418 Price More Price(3)

Brand: Sigma-Aldrich(India)
Product number: A3230
Product name : AR-A014418
Purity: ≥98% (HPLC), solid
Packaging: 5MG
Price: ₹16421.53
Updated: 2022/06/14
Buy: Buy

Brand: Sigma-Aldrich(India)
Product number: A3230
Product name : AR-A014418
Purity: ≥98% (HPLC), solid
Packaging: 25MG
Price: ₹65675.28
Updated: 2022/06/14
Buy: Buy

Brand: Sigma-Aldrich(India)
Product number: 361549
Product name : GSK-3β Inhibitor VIII - CAS 487021-52-3 - Calbiochem
Purity: The GSK-3β Inhibitor VIII, also referenced under CAS 487021-52-3, controls the biological activity of GSK-3β. This small molecule/inhibitor is primari
Packaging: 5MG
Price: ₹16670.01
Updated: 2022/06/14
Buy: Buy

AR-A014418 Chemical Properties,Usage,Production

Description AR-A 014418 (487021-52-3) is a selective glycogen synthase kinase 3 (GSK-3) inhibitor, IC50 = 104 nM. Inhibits β-amyloid-mediated neurodegeneration in hippocampal slices. Anti-inflammatory activity. Cell permeable. Active in rodent models.
Chemical Properties Pale Yellow Solid
Uses AR-A014418 has been used as an inhibitor of glycogen synthase kinase 3 (GSK3).
Uses Glycogen Synthase Kinase 3β (GSK-3β) inhibitor.
General Description A cell-permeable thiazole-containing urea compound that acts as a potent inhibitor of GSK-3. Shown to inhibit GSK-3β with high potency (IC₅₀ = 104 nM). Inhibition is competitive with respect to ATP (K_i = 38 nM). Specificity has been reported using a panel of 28 different kinases, including Cdk2 and Cdk5 (IC₅₀ >100 μM). Shown to prevent tau phosphorylation at a GSK-3-specific site. Also shown to protect neuronal cells against Aβ-mediated neurodegeneration in vitro and reduce tauopathy in mice in vivo (30 μmol/kg delivered with 40% PEG400 and 40% dimethylacetamide in water). Caution: Do not use delivering vehicles containing dimethylamine for in vivo studies, as it is highly toxic to animals. A 25 mM (5 mg/649 μl) solution of GSK-3β Inhibitor VIII (Cat. No. 361557) in DMSO is also available.
Biochem/physiol Actions Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer′s disease. GSK3 inhibitor, AR-A014418, inhibits GSK3 (IC50 = 104 nM), in an ATP-competitive manner (Ki = 38 nM). AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC50 > 100 μM) or 26 other kinases, demonstrating high specificity for GSK3.
in vitro ara014418 acted as an atp-competitive manner and did not significantly inhibit cdk2 or cdk5 or 26 other kinases demonstrating high specificity for gsk3. ar-a014418 inhibited tau phosphorylation at a gsk3-specific site (ser-396) in cells stably expressing human four-repeat tau protein [1].
in vivo ara014418 induced behavioural changes that were consistent with the effects of antidepressant drugs. subacute intraperitoneal injections of ar-a014418 reduced immobility time in rats exposed to the forced swim test, which was a well-established model for antidepressant efficacy. moreover, the specificity of this effect was supported by our finding that ar-a014418 decreased spontaneous as well as amphetamine-induced activity [2].
Enzyme inhibitor This ATP-competitive protein kinase inhibitor (FW = 308.31 g/mol; CAS 487021-52-3; Solubility: 62 mg/mL DMSO; <1 mg/mL H2O) selectively targets glycogen synthase kinase 3β (GSK3β),with IC50 = 104 nM; Ki = 38 nM. Attesting to its high specificity for GSK3, AR-A014418 does not significantly inhibit Cdk2 or Cdk5 (IC50 > 100 μM) or 26 other kinases. AR-A014418 inhibits phosphorylation of the microtubule-associated protein Tau at Ser-396 (i.e., the GSK3-specific site) in cells stably expressing human four-repeat Tau. AR-A014418 protects N2A neuroblastoma cells against cell death mediated by inhibition of the phosphatidylinositol 3-kinase/protein kinase B survival pathway. AR- A014418 inhibits neurodegeneration mediated by b-amyloid peptide in hippocampal slices. Treatment of neuroblastoma cell lines with AR- A014418 reduced the level of GSK-3α phosphorylation at Tyr-279 compared to GSK-3β phosphorylation at Tyr-216, and attenuated growth via the maintenance of apoptosis.. AR-A014418-dependent antinociceptive effects are induced by modulation of the glutamatergic system through metabotropic and ionotropic (NMDA) receptors and the inhibition of TNF-α and IL-1β cytokine signaling.
IC 50 104 ± 27 nm
storage +4°C
References 1) Bhat et al. (2003), Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418; J. Biol. Chem., 278 45937 2) Ramirez et al. (2010), Inhibition of glycogen synthase kinase 3beta (GSK3β) decreases inflammatory responses in brain endothelial cells; Am. J. Pathol., 176 881